Physician-Supervised • Registered Nurses & Nurse Practitioners • Backed by Clinical Research
At Injectco, we make the most advanced weight loss science available to adults across the United States. Our nationwide Retatrutide program combines clinical expertise, personalized care, and the convenience of same-day shipping so you can begin your transformation without delay. Every patient receives a free, private telehealth consultation with a registered nurse or nurse practitioner, under the direct supervision of a licensed medical doctor.
Retatrutide is more than just another weight loss injection — it’s a triple-hormone peptide therapy currently in clinical development by Eli Lilly & Company, delivering unprecedented results in controlled studies. Our mission is to bring this breakthrough therapy to qualified adults nationwide through a safe, medically-supervised, and fully customized program.
Whether you live in a busy city or a rural town, we’re here to provide expert guidance, transparent pricing, and fast access to treatment — all without leaving your home.
Retatrutide is a next-generation investigational weight loss medication that activates three key metabolic pathways in the body — GLP-1, GIP, and glucagon receptors — to deliver deeper, more sustained weight loss than existing single or dual-agonist therapies.
This unique triple-action approach makes Retatrutide a powerful new option for adults struggling with obesity or weight-related health conditions such as type 2 diabetes, metabolic syndrome, and cardiovascular risk factors.
While still in the FDA clinical trial process, Retatrutide has been featured in The New England Journal of Medicine and discussed at the American Diabetes Association Scientific Sessions for its unmatched results — including average weight loss of up to 24.2% in 48 weeks.
Our program provides controlled, physician-supervised access to compounded Retatrutide in states where it is permitted, with safe dosing protocols, ongoing monitoring, and nurse-led support.
Retatrutide’s potential is supported by some of the most compelling obesity treatment data ever published.
In Eli Lilly’s Phase 2 SURMOUNT trials, Retatrutide participants experienced unprecedented weight loss results:
These outcomes outperformed Semaglutide and Tirzepatide results from similar patient populations in earlier trials.
The NEJM peer-reviewed publication detailed Retatrutide’s triple agonist mechanism and confirmed its statistical superiority in weight loss compared to placebo and existing GLP-1-based therapies.
📄 Read the NEJM Retatrutide Study
At the 83rd ADA Scientific Sessions, Retatrutide was highlighted as a game-changing therapy for both obesity and type 2 diabetes management. Presenters noted not only the magnitude of weight loss but also its positive metabolic ripple effects, such as improved insulin sensitivity and reduced inflammation markers.
📄 Learn More on the ADA Website
Where other medications address two metabolic pathways at most, Retatrutide’s triple receptor engagement allows for:
This combined action may explain its ability to push weight loss beyond the plateau seen with other therapies.
Retatrutide’s effectiveness comes from its triple-hormone receptor activation, targeting three critical pathways that regulate weight, metabolism, and energy balance. This multi-pathway approach gives it a unique edge over other GLP-1-based medications.
When GLP-1, GIP, and glucagon are all activated together, they produce a compounding effect:
This synergy helps break the weight loss plateau that often occurs with single- or dual-pathway medications.
| Feature / Pathway | Semaglutide (GLP-1) | Tirzepatide (GLP-1 + GIP) | Retatrutide (GLP-1 + GIP + Glucagon) |
|---|---|---|---|
| Appetite Suppression | ✅ | ✅ | ✅ |
| Blood Sugar Control | ✅ | ✅ | ✅ |
| Energy Expenditure Boost | ❌ | ❌ | ✅ |
| Fat Metabolism Activation | ❌ | ❌ | ✅ |
| Average Weight Loss (48 wks) | ~15% | ~21% | Up to 24.2% |
While Semaglutide (Ozempic®, Wegovy®) and Tirzepatide (Mounjaro®, Zepbound®) have transformed obesity treatment, Retatrutide takes it one step further by engaging an additional fat-burning pathway.
Key Differences:
This makes Retatrutide an appealing choice for patients who have tried other GLP-1 medications but hit a plateau or want the most aggressive evidence-based option available under medical supervision.
Retatrutide may be a strong fit for:
Note: Retatrutide is still an investigational therapy; patient eligibility and state regulations determine access. All programs are fully MD-supervised with nurse-administered telehealth care to ensure safety.
At Injectco, we believe advanced medical weight loss therapy should be safe, accessible, and personalized — no matter where you live. Our team is made up of licensed registered nurses (RNs) and nurse practitioners (NPs) working under the direct supervision of board-certified medical doctors. Every patient interaction is designed to meet the highest standards of medical ethics, safety, and results-focused care.
We serve patients in all 50 states where Retatrutide access is permitted, including:
Retatrutide’s effectiveness comes from its triple-hormone receptor activation, targeting three critical pathways that regulate weight, metabolism, and energy balance. This multi-pathway approach gives it a unique edge over other GLP-1-based medications.
We’ve designed our program to make starting Retatrutide therapy simple, safe, and fast — no matter where you live.
Why it works: This model ensures you’re not just getting a medication — you’re receiving a fully managed medical weight loss program built for real-world success.
While Retatrutide’s FDA-approved dosing guidelines are still pending due to its investigational status, our protocols follow the latest clinical research data combined with best practices for patient safety.
Our compounded Retatrutide is prepared at a 2.5 mg/mL concentration using a 5 mg vial reconstituted with 2 mL bacteriostatic water.
Example: A 4 mg weekly dose equals 1.6 mL (160 units) using a 0.5 mL insulin syringe.
(For illustrative purposes — actual schedules may differ based on patient needs)
| Week Range | Weekly Dose (mg) | Weekly Injection Volume (mL) | Purpose |
|---|---|---|---|
| Weeks 1–4 | 2 mg | 0.8 mL | Initial tolerance phase |
| Weeks 5–8 | 3 mg | 1.2 mL | Increased metabolic activation |
| Weeks 9–12 | 4 mg | 1.6 mL | Target clinical trial maintenance dose |
| Weeks 13+ | 4 mg (adjustable) | 1.6 mL | Maintenance or further optimization |
Note: Doses may be reduced, paused, or adjusted depending on patient response and side effect profile.
Every Retatrutide prescription through Injectco includes:
Signature-required shipping to protect medication integrity
Every patient’s journey is unique, but clinical trial data and our nationwide patient outcomes give us a clear picture of what’s possible with Retatrutide under medical supervision.
Month 1
Months 2–3
Months 4–6
Months 7–12
Like all GLP-1-based therapies, Retatrutide can produce side effects — particularly during the dose escalation phase. Our medical team is trained to help patients minimize and manage these reactions so treatment remains safe and effective.
Every Injectco patient benefits from continuous oversight to ensure safety:
While most side effects are mild, you should stop treatment and contact us right away if you experience:
Our nurses are available daily until 8:30 PM Eastern to provide support, and emergency protocols are in place for after-hours needs.
We believe in transparent, all-inclusive pricing — so you know exactly what you’re getting before you begin.
Pricing varies based on:
While Retatrutide is still an investigational medication, our compounded formulation allows eligible patients nationwide to access this therapy under strict medical supervision. We work to keep costs competitive compared to other GLP-1-based treatments, especially when factoring in our included services.
Transparent communication about expected timelines and results
Other clinics may offer a lower price point for medication alone, but Injectco’s program includes continuous medical oversight, personalized care, and secure, same-day delivery — ensuring you get results safely and without delays.
Currently, most insurance plans do not cover Retatrutide due to its investigational status. Our program is structured as an out-of-pocket investment in your health, and we accept multiple payment methods for your convenience.
Injectco’s nurse-led, MD-supervised Retatrutide program is available to eligible patients across the United States. Whether you live in a major metro area or a smaller community, our telehealth consultations, same-day prescription processing, and signature-required nationwide shipping ensure you can start treatment quickly and safely.
For patients in major metro areas, we’ve built dedicated pages with localized resources and state-specific guidance:
Retatrutide is an investigational triple-hormone peptide therapy developed by Eli Lilly. It works by activating GLP-1, GIP, and glucagon receptors — a combination that reduces appetite, improves insulin function, and increases fat metabolism. This triple-action approach has shown greater weight loss in clinical trials compared to single or dual-agonist medications like Semaglutide (Ozempic®) and Tirzepatide (Mounjaro®).
Yes — while Retatrutide is still in the FDA clinical trial phase, compounded formulations are available in certain states under strict medical supervision. At Injectco, we provide nationwide access through a telehealth program led by registered nurses and nurse practitioners, with MD oversight. We offer same-day prescription processing and secure, signature-required shipping.
In Eli Lilly’s SURMOUNT Phase 2 trials, patients lost an average of 17.5% of body weight by week 24 and up to 24.2% by week 48. Individual results vary depending on dosage, adherence, and lifestyle factors, but these numbers outperform most other GLP-1 weight loss injections currently available.
This extra pathway engagement helps many patients break through weight loss plateaus.
Yes. Retatrutide has shown significant improvements in A1C, fasting glucose, lipid profiles, and insulin sensitivity. These benefits make it promising for patients with type 2 diabetes, prediabetes, or metabolic syndrome — though eligibility is determined through a free telehealth consultation.
We share anonymized patient success stories to show real-world results. For example, one patient lost 64 lbs (22.7% of body weight) in 9 months, while another lost 39 lbs in 6 months — both under nurse-led supervision with same-day shipping.
You can schedule a free nurse-led telehealth consultation with Injectco — available daily until 8:30 PM Eastern / 5:30 PM Pacific. If you qualify, your prescription is processed the same day and shipped directly to your home, with signature required for security.
Retatrutide is administered under strict RN/NP supervision with MD oversight. Side effects are similar to other GLP-1 medications — including mild nausea, GI discomfort, or constipation — and are usually temporary. We use a gradual dose escalation protocol to minimize issues.
Costs vary depending on dosage and program length. Our pricing includes the medication, free telehealth consults, same-day shipping, and ongoing nurse follow-up — offering more value than medication-only options.
Injectco serves patients nationwide, including major metro areas like New York, Miami, Chicago, Dallas, Los Angeles, Seattle, and Orlando, as well as smaller cities and rural communities through secure nationwide shipping.
